Góreczny Sebastian, Dryżek Paweł, Morgan Gareth J, Mazurek-Kula Anna, Moll Jacek J, Moll Jadwiga A, Qureshi Shakeel, Moszura Tomasz
Department of Cardiology, Polish Mother's Memorial Hospital, Research Institute, Lodz, Poland.
Department of Congenital Heart Disease, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Arch Med Sci. 2017 Mar 1;13(2):337-345. doi: 10.5114/aoms.2016.61836. Epub 2016 Nov 28.
Creation of a fenestration during completion of a total cavopulmonary connection (TCPC) has been associated with a reduction in early mortality and morbidity. However, the long-term benefits are negated by an associated limitation in exercise tolerance and the potential risks of thrombo-embolic complications. We sought to describe the safety and efficacy of an Amplatzer Duct Occluder II (ADO II) for transcatheter fenestration closure following TCPC.
Between January 2000 and July 2014, 102 patients underwent percutaneous closure of extra-cardiac TCPC fenestrations with a range of devices. Patients in whom fenestration closure was performed with an ADO II and who had at least 6 months of follow-up were included in this study.
Forty-seven patients had successful fenestration occlusion with an ADO II. The mean oxygen saturation and mean systemic venous pressures increased from 84.8 ±6.1% before to 97.6 ±2.9% ( < 0.001) after and from 14.2 ±2.15 mm Hg before to 15.6 ±2.2 mm Hg after closure ( < 0.001). Eight patients developed heart failure symptoms, managed by optimization of medical therapy, with 1 patient requiring device removal to reopen the fenestration. Color Doppler transthoracic echocardiography demonstrated residual flow across the device in 18 (38%), 10 (22%), 5 (11%) and 4 (9%) patients before discharge, at 1 and 6 months, and at the latest outpatient visit, respectively.
The ADO II can be safely and effectively used to close fenestrations in extra-cardiac type Fontan completions. Many of the design features of this device confer potential benefit in this population.
在完全腔肺连接(TCPC)完成过程中创建一个开窗与早期死亡率和发病率的降低有关。然而,运动耐量的相关限制以及血栓栓塞并发症的潜在风险抵消了其长期益处。我们试图描述使用Amplatzer II型动脉导管封堵器(ADO II)进行经导管封堵TCPC术后开窗的安全性和有效性。
2000年1月至2014年7月期间,102例患者使用一系列装置经皮封堵心外TCPC开窗。本研究纳入了使用ADO II进行开窗封堵且至少随访6个月的患者。
47例患者使用ADO II成功封堵开窗。平均血氧饱和度和平均体静脉压分别从术前的84.8±6.1%升至术后的97.6±2.9%(P<0.001),以及从术前的14.2±2.15 mmHg升至封堵后的15.6±2.2 mmHg(P<0.001)。8例患者出现心力衰竭症状,通过优化药物治疗进行处理,其中1例患者需要取出装置以重新打开开窗。彩色多普勒经胸超声心动图显示,出院前、术后1个月、6个月及最近一次门诊随访时,分别有18例(38%)、10例(22%)、5例(11%)和4例(9%)患者的装置处存在残余血流。
ADO II可安全有效地用于封堵心外类型Fontan手术的开窗。该装置的许多设计特点对这一人群具有潜在益处。